SOL-116靶向胆汁盐刺激脂肪酶的首个人体I期试验
该随机双盲安慰剂对照首个人体试验在48名健康参与者和8名类风湿关节炎患者中评估了靶向胆汁盐刺激脂肪酶(BSSL)的人源化IgG4单抗SOL-116。SOL-116在测试剂量下安全且耐受良好,药代动力学呈剂量比例增加,并有效降低循环游离BSSL水平,支持其后续临床开发。
要点
- SOL-116在健康参与者和RA患者中安全且耐受良好。
- 单次给药后AUC和Cmax呈剂量比例增加,健康参与者与RA患者PK特征相当。
- SOL-116有效降低循环游离BSSL水平,证实靶点结合。
核心结论
- SOL-116具有良好的安全性和药代动力学特征,并有效降低循环游离BSSL水平,支持其针对RA等慢性炎症的后续临床开发。
研究设计与样本
- 随机、双盲、安慰剂对照的首个人体研究,在48名健康参与者中评估单次递增剂量(0.075-6.075 mg/kg)和多次剂量(3.0 mg/kg每4周共4次)皮下给药,并在8名RA患者中评估单次剂量(2.025 mg/kg)。
主要发现
- SOL-116在测试剂量水平下安全且耐受良好。
- 健康参与者单次给药队列中AUC和Cmax呈剂量比例增加,健康参与者与RA患者PK特征相当,抗药抗体频率低。
- SOL-116有效降低循环游离BSSL水平,证实靶点结合,但其他探索性炎症标志物未见明显变化。
临床怎么用
- SOL-116在测试剂量下安全耐受且能有效结合并降低循环游离BSSL,支持在RA等慢性炎症中进一步开展疗效和机制研究。
局限性
- 其他探索性炎症标志物未见明显变化,SOL-116的疗效和BSSL在慢性炎症中的作用机制尚待进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Bile salt-stimulated lipase (BSSL) is a digestive lipolytic enzyme and a potential novel drug target for treatment of rheumatoid arthritis (RA). Here, we report the results of the first-in-human study of SOL-116, a first-in-class humanised IgG4 monoclonal antibody targeting BSSL, conducted in healthy participants and patients with RA. METHODS: This was a randomised, double-blind, placebo-controlled study of ascending single doses (0.075-6.075 mg/kg) and multiple doses (4 doses of 3.0 mg/kg every 4 weeks) of subcutaneously administered SOL-116 in healthy participants, as well as a single dose (2.025 mg/kg) in patients with RA. Safety and tolerability were assessed as the primary objective and pharmacokinetics (PK) and immunogenicity as secondary objectives. Exploratory objectives included evaluating BSSL concentrations and inflammatory markers. RESULTS: SOL-116 was safe and well tolerated at the tested dose levels in 48 healthy participants and 8 patients with RA. There was a dose-proportional increase in area under the curve and maximum concentration across the single dose cohorts in healthy participants, with comparable PK characteristics between healthy participants and patients with RA and a low frequency of anti-drug antibodies. Notably, SOL-116 effectively reduced free BSSL levels in circulation, confirming target engagement although no clear changes in other exploratory inflammation markers were observed. CONCLUSIONS: This study demonstrated that SOL-116 has a favourable safety and PK profile. Combined with effective reduction of free BSSL in the circulation, findings in this study support ongoing clinical development of SOL-116, with a focus on elucidating the efficacy and mechanism of action of BSSL in the treatment of chronic inflammation, primarily RA. TRIAL REGISTRATION NUMBER: NCT05576012.
引用
- Meijs AC, Kolmert J, Lindquist S, et al. First-in-human (phase I) trial of SOL-116, a humanised IgG4 monoclonal antibody targeting bile salt-stimulated lipase, in healthy participants and rheumatoid arthritis patients. RMD Open. 2026. PMID: 42331396. doi:10.1136/rmdopen-2026-006712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。